In a nutshell This study evaluated how well crizotinib (Xalkori) works in patients with non-small cell lung cancer (NSCLC) with an ALK mutation that had spread to the brain. This study found that crizotinib treatment improved survival, but not for patients with cancer in the brain that continued to grow. Some background NSCLC is the most common type...
Read More
In a nutshell This study investigated the safety and effectiveness of crizotinib (Xalkori) in advanced non-small cell lung cancer (NSCLC). They found that this treatment improved survival in advanced NSCLC. Some background Standard therapy for NSCLC involves chemotherapy and radiation. Patients with advanced NSCLC may not respond to...
Read MoreIn a nutshell This study investigated second-line treatments for non-small cell lung cancer (NSCLC). They found that second-line options are effective in advanced NSCLC. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Many cases of NSCLC are diagnosed at an advanced stage. First-line treatment...
Read More
In a nutshell This study investigated the effect of pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). They found that this treatment was effective as a first-line therapy for NSCLC. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients with advanced NSCLC are usually treated...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of durvalumab (Imfinzi) and monalizumab to treat patients with solid tumors, including lung cancer. The main outcomes to be measured are tumor response to the treatment and side effects. The details Cancer is one of the leading causes of death worldwide. Chemotherapy is only of limited...
Read MoreIn a nutshell This trial is examining a new anti-cancer medication for non-small cell lung cancer called tislelizumab. The main outcome that will be measured is how long it takes for the cancer to start growing again. This study is recruiting across the United States. The details Non-small cell lung cancer (NSCLC) can be...
Read More
In a nutshell This study evaluated the effectiveness of pembrolizumab (Keytruda) versus platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). This study found that pembrolizumab treatment resulted in longer overall survival than treatment with platinum-based chemotherapy. Some background NSCLC is the...
Read More
In a nutshell This study determined whether osimertinib (Tagrisso) was more effective than erlotinib (Tarceva) in patients with non-small cell lung cancer (NSCLC) with the EGFR mutation. The study found that treatment with osimertinib improved survival compared to standard-care treatment for these patients. Some background...
Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of a new targeted therapy drug, INCMGA00012 in metastatic (spread to other organs) non-small cell lung cancer (NSCLC). The main outcome will be the overall response rate. This trial is recruiting in Texas, United States. The details NSCLC is the most common form of...
Read More
In a nutshell This phase 3 trial will investigate the effectiveness of pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). The main outcomes will be the rates of survival without any signs and symptoms of cancer and overall survival. The details NSCLC is usually treated with a combination of surgery to remove tumors and...
Read MoreIn a nutshell This phase 3 trial will investigate the effectiveness of cemiplimab (Libtayo) and ipilimumab (Yervoy) in combination with platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). The main outcome will be response to treatment and survival without cancer growing or spreading. The...
Read More
In a nutshell This study investigated the effectiveness of bevacizumab (Avastin) in combination with platinum-based chemotherapy in Hungarian patients with non-small-cell lung cancer (NSCLC). They found that this treatment combination was associated with improved patient survival. Some background The most common type of lung cancer is...
Read More
